Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India's Medanta promises step-change in hi-tech access with Siemens contract

This article was originally published in Clinica

Executive Summary

Under what is being billed as one of India's largest private healthcare industry contracts, Siemens is introducing to the country a range of its scanning and cathlab systems for the first time. The imaging and IT systems partnership with Medanta-The Medicity, in Gurgaon (Haryana state), a satellite city of New Delhi, will see the launch of the Somatom Definition Flash CT scanner, the Artis Zeego cathlab, Acuson SC2000 ultrasound system and the PET/CT scanner Biograph mCT. The Medanta complex, which features 300 critical beds, 45 operating theatres and a research centre, is promising to offer the "range of first-of-its-kind technology while providing care at an affordable cost". Siemens in India has reported an annual business volume of Rs11,800 crore (US$2.44bn), at September 2008.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT044029

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel